Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11193-11198

  Christ, Torsten ^a,c   Rozmaritsa, Nadiia ^a,d   Engel, Andreas ^a   Berk, Emanuel ^a,e   Knaut, Michael ^a   Metzner, Katharina ^a,f   Canteras, Manuel ^b   Ravens, Ursula ^a   Kaumann, Alberto ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL L TYPE; CATECHOLAMINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NORADRENALIN; PHOSPHOLAMBAN; RYANODINE; RYANODINE 2; SERINE; SEROTONIN; THREONINE; UNCLASSIFIED DRUG;

ARRHYTHMOGENESIS; ARTICLE; CALCIUM TRANSPORT; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM TRABECULUM; HEART CONTRACTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INOTROPISM; PRIORITY JOURNAL; PROTEIN DOMAIN; REDUCTION; SINUS RHYTHM;

ATRIAL FIBRILLATION; CALCIUM; CALCIUM CHANNELS, L-TYPE; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOTONIC AGENTS; CATECHOLAMINES; CHRONIC DISEASE; COLFORSIN; CYCLIC AMP; FEMALE; HEART ATRIA; HUMANS; MALE; MYOCARDIAL CONTRACTION; PHOSPHORYLATION; RYANODINE; SEROTONIN; SEROTONIN RECEPTOR AGONISTS;

EID: 84905050495     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1324132111     Document Type: Article

References (34)

1. Lloyd-Jones DM, et al. (2004) Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 110(9):1042-1046. (Pubitemid 39319000)
2. Manning WJ, et al. (1994) Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol 23(7):1535-1540. (Pubitemid 24182115)
3. Schotten U, et al. (2001) Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 103(5):691-698. (Pubitemid 32144198)
4. Van Wagoner DR, et al. (1999) Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 85(5):428-436. (Pubitemid 29409619)
5. 2-adrenoceptors in human atrial myocardium from non-failing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol 375(1):11-28.
6. Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ (1990) A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol 100(4):879-885. (Pubitemid 20233335)
7. Gergs U, et al. (2009) Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 379(4):349-359.
8. 2-adrenoceptors mediate catecholamineevoked arrhythmias in isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol 348(5):536-540.
9. Kaumann AJ, Sanders L (1994) 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: Facilitation by chronic β-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol 349(4):331-337. (Pubitemid 24110202)
10. Kalman JM, et al. (1995) Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 60(6):1709-1715. (Pubitemid 26079160)
11. 2+ handling in human chronic atrial fibrillation. Circulation 114(7):670-680.
12. Vest JA, et al. (2005) Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111(16):2025-2032. (Pubitemid 40577896)
13. 2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 106(6):1134-1144.
14. Seamon KB, Padgett W, Daly JW (1981) Forskolin: Unique diterpene activator of adenylate cyclase inmembranes and in intact cells. Proc Natl Acad Sci USA 78(6):3363-3367. (Pubitemid 11059290)
15. Pau D, Workman AJ, Kane KA, Rankin AC (2007) Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation. J Mol Cell Cardiol 42(1):54-62. (Pubitemid 44958612)
16. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415(6868):198-205.
17. Van Haastert PJ, et al. (1984) Competitive cAMP antagonists for cAMP-receptor proteins. J Biol Chem 259(16):10020-10024. (Pubitemid 14067669)
18. Schotten U, et al. (2002) Atrial fibrillation-induced atrial contractile dysfunction: A tachycardiomyopathy of a different sort. Cardiovasc Res 53(1):192-201. (Pubitemid 34020780)
19. 2+ current down-regulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110(17):2651-2657.
20. 2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 125(17):2059-2070.
21. 2+ transient in rat myocytes during β-adrenergic stimulation. J Physiol 505(Pt 2):385-402.
22. 2+ release in cardiomyocytes during beta-adrenergic stimulation. J Physiol 588(Pt 1):225-242.
23. Hatem SN, et al. (1997) Different compartments of sarcoplasmic reticulum participate in the excitation-contraction coupling process in human atrial myocytes. Circ Res 80(3):345-353. (Pubitemid 27093348)
24. Koivumäki JT, Korhonen T, Tavi P (2011) Impact of sarcoplasmic reticulum calcium release on calcium dynamics and action potential morphology in human atrialmyocytes: A computational study. PLOS Comput Biol 7(1):e1001067.
25. Wei SK, Hanlon SU, Haigney MC (2002) Beta-adrenergic stimulation of pig myocytes with decreased cytosolic free magnesium prolongs the action potential and enhances triggered activity. J Cardiovasc Electrophysiol 13(6):587-592. (Pubitemid 34615426)
26. Curran J, Hinton MJ, Ríos E, Bers DM, Shannon TR (2007) Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res 100(3):391-398.
27. Sag CM, et al. (2009) Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ Heart Fail 2(6):664-675.
28. Lo L-W, et al. (2007) Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins. Eur J Pharmacol 571(2-3):197-208. (Pubitemid 47385897)
29. Grimm M, Brown JH (2010) Beta-adrenergic receptor signaling in the heart: Role of CamKII. J Mol Cell Cardiol 48(2):322-330.
30. 2+/calmodulin-dependent kinase II (CaMKII). Circulation 126(17):2125-2139.
31. K,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation 104:2551-2557.
32. 2- adrenoceptors in human atrium: Functional implications. Naunyn Schmiedebergs Arch Pharmacol 353(5):592-595.
33. Swedberg K, et al. (2005) Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET. Eur Heart J 26(13):1303-1308. (Pubitemid 41435461)
34. Kao DP, et al. (2013) Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail 15(3):324-333.